Shop
Cart Details

WEGOVY (semaglutide)* 2.4mg

  • Manufacturer Name : NOVO NORDISK
  • MFG # : 00169-4524-14
  • NDC : 00169452414
  • Distributor Name : The Pharmacy Hub
PID UOM Price Qty
639229 1/EA Register For Member Price
Register For Member Price

 

Additional Information

Brand NameWEGOVY®
Generic NameSemaglutide
Dosage FormPre-filled single-dose pen (subcutaneous injection)
Strength2.4 mg / 0.75 mL
Pharmacological ClassGLP-1 (Glucagon-like Peptide-1) Receptor Agonist
Indications

• Chronic weight management in adults with obesity (BMI =30 kg/m²) or overweight (BMI =27 kg/m²) with =1 weight-related comorbidity .

• Chronic weight management in pediatric patients aged =12 years with obesity (BMI =95th percentile) and body weight >60 kg .

• Reduction of MACE risk (cardiovascular death, non-fatal MI, or non-fatal stroke) in adults with established CVD and either obesity or overweight .

• Treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2–F3).

AdministrationAdminister subcutaneously in abdomen, thigh, or upper arm; rotate sites weekly. Can be given with or without food at any time of day.
Key MechanismGLP-1 receptor agonism reduces appetite via central nervous system actions, delays gastric emptying, and enhances glucose-dependent insulin secretion while suppressing glucagon.
Contraindications
  • Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
  • Serious hypersensitivity to semaglutide or any excipients.
Warnings & Precautions
  • Thyroid C-cell tumors: Rodent studies show risk; monitor for neck masses, dysphagia, dyspnea, or hoarseness.
  • Pancreatitis: Discontinue if suspected.
  • Gallbladder disease: Increased risk of cholelithiasis and cholecystitis.
  • Hypoglycemia: Higher risk when used with insulin or sulfonylureas; monitor blood glucose in diabetics.
  • Acute kidney injury: Risk from dehydration due to GI adverse reactions; ensure adequate hydration.
  • Diabetic retinopathy: Monitor in patients with type 2 diabetes.
  • Suicidal behavior/ideation: Monitor for depression or mood changes.
  • Pulmonary aspiration: Risk during anesthesia/sedation; withhold dose prior to procedures.
Common Adverse ReactionsNausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), abdominal pain (20%), headache (14%), fatigue (11%), dyspepsia (9%), dizziness (7%), hypoglycemia in diabetics (6%) .
Drug Interactions
  • May delay gastric emptying and affect absorption of oral medications.
  • Concomitant use with insulin or sulfonylureas increases hypoglycemia risk; consider dose reduction.
Patient Counseling
  • Instruct on proper injection technique and site rotation.
  • Advise on dietary strategies to manage GI side effects (e.g., small, low-fat meals)
  • Monitor for signs of thyroid tumors, pancreatitis, hypoglycemia, or suicidal thoughts.
  • Inform anesthesiologists of use prior to elective surgery.
How SuppliedPre-filled pens in strengths of 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg per 0.75 mL.

Product Description

WEGOVY® (semaglutide) 2.4 mg is a once-weekly GLP-1 (glucagon-like peptide-1) receptor agonist indicated for chronic weight management in adults and pediatric patients aged 12 years and older with obesity (BMI =30 kg/m² or =95th percentile for age and gender) or overweight (BMI =27 kg/m² in adults) with at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, cardiovascular disease), as well as to reduce the risk of major adverse cardiovascular events (MACE) such as cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke in adults with established cardiovascular disease and either obesity or overweight, adjunct to a reduced-calorie diet and increased physical activity. Its mechanism of action involves selectively activating GLP-1 receptors in the brain to reduce appetite and promote satiety, in the pancreas to enhance glucose-dependent insulin secretion and suppress glucagon release, and in the gastrointestinal tract to delay gastric emptying, collectively leading to significant and sustained weight loss (averaging 15% of body weight at 68 weeks in clinical trials) and improved metabolic parameters. The 2.4 mg dose represents the maintenance strength following a 16-week titration schedule to minimize gastrointestinal adverse effects, with careful monitoring recommended for potential risks including thyroid C-cell tumors, pancreatitis, hypoglycemia when used with insulin or sulfonylureas, and dehydration-related acute kidney injury.

Frequently Asked Questions(FAQs)

The cost of WEGOVY (semaglutide)* 2.4mg is $0.00 .
WEGOVY (semaglutide)* 2.4mg is manufactured by NOVO NORDISK.
Read More

Subscribe to Our Newsletter